More Notable Trials From SABCS 2008

By Guest Editor Aman U. Buzdar, MD The University of Texas MD Anderson Cancer Center | February 1, 2009

Eidtmann H et al: The effect of zoledronic acid(Drug information on zoledronic acid) on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole(Drug information on letrozole): 36 months follow-up of ZO-FAST (abstract 44).

Dowsett M et al: Risk of distant recurrence using Oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole(Drug information on anastrozole) or tamoxifen: A TransATAC study (abstract 53).

Bartlett JMS et al: A prospectively planned pathology study within the TEAM trial confirms that progesterone(Drug information on progesterone) receptor expression is prognostic but is not predictive for differential response to exemestane(Drug information on exemestane) versus tamoxifen(Drug information on tamoxifen) (abstract 81).

SUPPLEMENTS BY YEAR

Topic Index

Cancer Types
Breast Breast (HER2+) Breast (Triple-Negative) CML Colorectal Gastrointestinal GIST Genitourinary Gynecologic Head & Neck	Hematology Kidney (Renal Cell) Leukemia Lung Lymphoma Melanoma Multiple Myeloma Ovarian Prostate Sarcoma
Supportive Care	More Topics
Bone Metastases End-of-Life Care Palliative Care	Ethics in Oncology Practice Management Practice & Policy